×
App Icon
The Standard e-Paper
Home To Bold Columnists
★★★★ - on Play Store
Read on the App

Kemri: TB vaccine trials promising, treatment period to reduce

Tuberculosis remains a leading killer disease in Kenya. [Courtesy]

The Kenya Medical Research Institute (KEMRI) has said that the clinical trials of its Tuberculosis (TB) vaccine for adults and children is promising.

Once the tests are conclusive, KEMRI says it would seek approval from the World Health Organization (WHO) to roll out the vaccine for public use.

Get Full Access for Ksh299/Week
Bold Reporting Takes Time, Courage and Investment. Stand With Us.
  • Unlimited access to all premium content
  • Uninterrupted ad-free browsing experience
  • Mobile-optimized reading experience
  • Weekly Newsletters
  • MPesa, Airtel Money and Cards accepted
Already a subscriber? Log in